BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 25265187)

  • 1. Treatment of bisphosphonate-resistant hypercalcemia of malignancy with calcitonin.
    Dawson C; Todd AM; Walton A
    J Palliat Med; 2014 Oct; 17(10):1084. PubMed ID: 25265187
    [No Abstract]   [Full Text] [Related]  

  • 2. Modern management of malignant hypercalcemia.
    Legrand SB
    Am J Hosp Palliat Care; 2011 Nov; 28(7):515-7. PubMed ID: 21724679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe Hypercalcemia in a Child With Acute Lymphoblastic Leukemia Relapse: Successful Management With Combination of Calcitonin and Bisphosphonate.
    Tagiyev A; Demirbilek H; Tavil B; Buyukyilmaz G; Gumruk F; Cetin M
    J Pediatr Hematol Oncol; 2016 Apr; 38(3):232-4. PubMed ID: 26907650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bisphosphonate Versus Bisphosphonate and Calcitonin for the Treatment of Moderate to Severe Hypercalcemia of Malignancy.
    Khan AA; Gurnani PK; Peksa GD; Whittier WL; DeMott JM
    Ann Pharmacother; 2021 Mar; 55(3):277-285. PubMed ID: 32885992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of malignancy associated hypercalcemia].
    Tai N; Inoue D
    Clin Calcium; 2014 Aug; 24(8):1223-8. PubMed ID: 25065875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Denosumab for the treatment of bisphosphonate resistant hypercalcemia in a hemodialysis patient.
    Dahmani O; Sophoclis C; Kebir M; Bouguern D; Sakho A; Demarchi P
    Saudi J Kidney Dis Transpl; 2017; 28(1):154-157. PubMed ID: 28098117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The management of hypercalcaemia in advanced cancer.
    Pettifer A; Grant S
    Int J Palliat Nurs; 2013 Jul; 19(7):327-31. PubMed ID: 24273809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RE: Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment.
    Adhikaree J; Newby Y; Sundar S
    J Natl Cancer Inst; 2015 Mar; 107(3):. PubMed ID: 25663690
    [No Abstract]   [Full Text] [Related]  

  • 9. Re: Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment.
    Tsuda M; Ishiguro H; Yano I; Toi M
    J Natl Cancer Inst; 2014 Jul; 106(7):. PubMed ID: 24906398
    [No Abstract]   [Full Text] [Related]  

  • 10. [Bone and calcium metabolism associated with malignancy. Malignancy-associated hypercalcemia.].
    Tai N; Inoue D
    Clin Calcium; 2018; 28(11):1503-1508. PubMed ID: 30374007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A case of resistant hypercalcemia of malignancy with a proposed treatment algorithm.
    McMahan J; Linneman T
    Ann Pharmacother; 2009 Sep; 43(9):1532-8. PubMed ID: 19622757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Preclinical and clinical profile of zoledronic acid (Zometa) for hypercalcemia of malignancy].
    Tomoo T; Suzuki M
    Nihon Yakurigaku Zasshi; 2005 Nov; 126(5):353-7. PubMed ID: 16394581
    [No Abstract]   [Full Text] [Related]  

  • 13. Hypercalcemia and gallium nitrate.
    Gucalp R
    J Support Oncol; 2004; 2(6):518-20. PubMed ID: 16329218
    [No Abstract]   [Full Text] [Related]  

  • 14. A combination of calcitonin and bisphosphonate for the emergency treatment of severe tumor-induced hypercalcemia.
    Luce K; O'Donnell DE; Morton AR
    Calcif Tissue Int; 1993 Jan; 52(1):70-1. PubMed ID: 8453509
    [No Abstract]   [Full Text] [Related]  

  • 15. Chronic Myeloid Leukemia Associated Hypercalcemia: A Case Report and Literature Review.
    Toro-Tobón D; Agosto S; Ahmadi S; Koops M; Bruder JM
    Am J Case Rep; 2017 Feb; 18():203-207. PubMed ID: 28239141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Answers to questions on hypercalcemia from PRAXIS No. 5].
    Praxis (Bern 1994); 2009 Mar; 98(6):347. PubMed ID: 19291645
    [No Abstract]   [Full Text] [Related]  

  • 17. Bisphosphonate or RANK-L inhibitor for tumour-induced hypercalcaemia?
    Bech A; Essink G; de Boer H
    Neth J Med; 2012 Jun; 70(5):250-1. PubMed ID: 22744931
    [No Abstract]   [Full Text] [Related]  

  • 18. Quality and Outcomes of Treatment of Hypercalcemia of Malignancy.
    Wright JD; Tergas AI; Ananth CV; Burke WM; Hou JY; Chen L; Neugut AI; Richards CA; Hershman DL
    Cancer Invest; 2015; 33(8):331-9. PubMed ID: 26068056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Medical treatment of malignant hypercalcemia].
    Eto S; Nakano Y; Okada Y
    Gan To Kagaku Ryoho; 1993 Dec; 20(15):2311-8. PubMed ID: 8259844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms and treatment of hypercalcemia of malignancy.
    Clines GA
    Curr Opin Endocrinol Diabetes Obes; 2011 Dec; 18(6):339-46. PubMed ID: 21897221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.